Journal article

Raising the stakes: Loss of efflux pump regulation decreases meropenem susceptibility in burkholderia pseudomallei

DS Sarovich, JR Webb, MC Pitman, LT Viberg, M Mayo, RW Baird, JM Robson, BJ Currie, EP Price

Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2018

Abstract

Background Burkholderia pseudomallei, the causative agent of the high-mortality disease melioidosis, is a gram-negative bacterium that is naturally resistant to many antibiotics. There is no vaccine for melioidosis, and effective eradication is reliant on biphasic and prolonged antibiotic administration. The carbapenem drug meropenem is the current gold standard option for treating severe melioidosis. Intrinsic B. pseudomallei resistance toward meropenem has not yet been documented; however, resistance could conceivably develop over the course of infection, leading to prolonged sepsis and treatment failure. Methods We examined our 30-year clinical collection of melioidosis cases to identify ..

View full abstract

University of Melbourne Researchers